<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02333045</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00074767</org_study_id>
    <nct_id>NCT02333045</nct_id>
  </id_info>
  <brief_title>Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women</brief_title>
  <acronym>MIP</acronym>
  <official_title>Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to understand the immune cells in the cervical fluid of in the blood and
      genital tract of HIV-negative healthy female volunteers and to see if these cells can be
      modified using a combined anti-viral and antiinflammatory drug called maraviroc, a medicine
      used in the treatment of HIV infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigator seeks to understand the immune cells in the cervical fluid of
      HIV-negative healthy female volunteers, and to see if these cells can be modified using a
      combined anti-viral and antiinflammatory drug called maraviroc, a medicine used in the
      treatment of HIV infection. Maraviroc works by preventing HIV from entering human immune
      cells by blocking a protein on the outside of these cells called the C-C chemokine receptor
      type 5 (CCR5) receptor. When maraviroc is bound to this protein, the virus cannot enter the
      cell. The investigator thinks that CCR5 antagonists could be particularly good drugs for HIV
      pre-exposure prophylaxis (PrEP) and could potentially be dosed in ways that are easier to
      take than the current drugs used for PrEP.

      In order to further evaluate this PrEP strategy, the investigator will first study the immune
      cells in the blood and genital tract of HIV-negative healthy female volunteers over the
      course of 3 months to see how these cells change over time and are affected by factors such
      as age, menstrual cycle, and genital infections.

      The amount of maraviroc compared with the drugs in the current drugs used for PrEP
      (tenofovir/ emtricitabine) in the blood and genital tract of HIV-negative healthy female
      volunteers before, during, and after they are given maraviroc versus tenofovir/ emtricitabine
      for 7 days will be measured. We will also study immune cells from the blood and genital tract
      from these women to see if maraviroc, tenofovir, or emtricitabine have an effect on these
      cells that would prevent them from becoming infected with HIV.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Minimal efficacy of maraviroc alone was found in preliminary data analysis of another study.
  </why_stopped>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">October 28, 2016</completion_date>
  <primary_completion_date type="Actual">October 28, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Count of Total Cells Obtained From Cervicovaginal Lavage Samples</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21</time_frame>
    <description>The count of CCR5+CD4+ T cells in the genital tract, before participants began study treatment, after 7 days of treatment, and during the post-treatment drug elimination period. The precise role of CCR5+CD4+ T cells in the female genital tract is unknown, however, higher cell counts may suggest the potential for more HIV target cells in the genital tract.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Steady-state Area Under the Plasma Concentration-time Curve of Study Drug</measure>
    <time_frame>7 days</time_frame>
    <description>Study drug concentrations will be measured from blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-state Area Under the Female Genital Tract Concentration-time Curve of Study Drug</measure>
    <time_frame>7 days</time_frame>
    <description>Study drug concentrations will be measured from female genital tract.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Truvada qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women will be assigned at random Truvada 1 tablet PO daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maraviroc 300 qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women will be assigned at random Maraviroc 300 mg PO daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada qd</intervention_name>
    <description>Truvada 1 tablet PO daily for 7 days</description>
    <arm_group_label>Truvada qd</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc 300 qd</intervention_name>
    <description>Maraviroc 300 mg PO daily for 7 days</description>
    <arm_group_label>Maraviroc 300 qd</arm_group_label>
    <other_name>Selzentry</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-44 years

          -  Must be biologically female (defined as sex at birth)

          -  HIV negative women with at least one of the following risk factors in the past 5 years

               1. Injection drug use or use of crack, cocaine, heroin, or methamphetamine

               2. Diagnosed with a sexually transmitted infection

               3. Unprotected sex with 3 or more men

               4. Having sex for drugs, money, or shelter

               5. Sex with a known HIV-positive man

               6. Having a partner meeting any of the preceding criteria

          -  Normal menses (within 22-35 day intervals) for at least 3 cycles

          -  No history of alcohol abuse, heart disease, or liver disease, or any other medical
             condition that would interfere with the conduct of the study, in the opinion of the
             study investigator

          -  No history of loop electrosurgical excision procedure (LEEP), conization, or
             cryosurgery

          -  Normal chemistry, liver function, and complete blood count panels at screening,
             including:

               1. Absolute neutrophil count (ANC) ≥ 750/mm3

               2. Hemoglobin ≥ 10.0 g/dL

               3. Platelet count ≥ 100,000/mm3

               4. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline
                  phosphatase ≤ 3 x Upper Limit Normal (ULN)

               5. Total bilirubin ≤ 2.5 x ULN

               6. Creatinine Clearance (CrCl) ≥ 60 mL/min as estimated by the Cockcroft-Gault
                  equation

          -  Negative hepatitis B surface antigen (HBsAg)

          -  No signs or symptoms of orthostasis

          -  No signs or symptoms of vaginal infection or genital ulcer disease at screening or
             untreated vaginal infection in the last 30 days

          -  Not receiving concurrent medications that interact with maraviroc (MVC) or any
             antiretrovirals (such as tenofovir/ emtricitabine [Truvada®]) for the purpose of HIV
             prevention

          -  Willing to use condoms for the duration of the study and abstain from sexual
             intercourse for 48 hours before each genital tract sampling

        Exclusion Criteria:

          -  Male sex (defined as sex at birth)

          -  Pregnant or breastfeeding

          -  Current use of systemic hormonal contraception

          -  Symptomatic vaginal infection or genital ulcer disease at screening or treatment for
             vaginal infection in the last two weeks

          -  Active malignancy for which the participant is undergoing evaluation and/or treatment

          -  Immunosuppressive medications (i.e, systemic steroids)

          -  Any surgery in the preceding 2 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anandi Sheth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Infectious Diseases Clinic (Ponce Clinic)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>January 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2015</study_first_posted>
  <results_first_submitted>November 15, 2017</results_first_submitted>
  <results_first_submitted_qc>November 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2017</results_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Anandi Sheth</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>HIV-negative</keyword>
  <keyword>Women</keyword>
  <keyword>At-risk</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Truvada</title>
          <description>Women randomized to receive one tablet of Truvada (200mg emtricitabine/300mg tenofovir) daily for 7 days.</description>
        </group>
        <group group_id="P2">
          <title>Maraviroc</title>
          <description>Women randomized to receive 300mg of Maraviroc daily for 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All individuals who gave informed consent to participate in the study and who met eligibility criteria are included in the baseline analysis description.</population>
      <group_list>
        <group group_id="B1">
          <title>Truvada</title>
          <description>Women randomized to receive one tablet of Truvada (200mg emtricitabine/300mg tenofovir) daily for 7 days.</description>
        </group>
        <group group_id="B2">
          <title>Maraviroc</title>
          <description>Women randomized to receive 300mg of Maraviroc daily for 7 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Count of Total Cells Obtained From Cervicovaginal Lavage Samples</title>
        <description>The count of CCR5+CD4+ T cells in the genital tract, before participants began study treatment, after 7 days of treatment, and during the post-treatment drug elimination period. The precise role of CCR5+CD4+ T cells in the female genital tract is unknown, however, higher cell counts may suggest the potential for more HIV target cells in the genital tract.</description>
        <time_frame>Baseline, Day 7, Day 14, Day 21</time_frame>
        <population>The analysis includes all available data collected during each study visit. Not all participants provided a sample at every study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Women randomized to receive one tablet of Truvada (200mg emtricitabine/300mg tenofovir) daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc</title>
            <description>Women randomized to receive 300mg of Maraviroc daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Total Cells Obtained From Cervicovaginal Lavage Samples</title>
          <description>The count of CCR5+CD4+ T cells in the genital tract, before participants began study treatment, after 7 days of treatment, and during the post-treatment drug elimination period. The precise role of CCR5+CD4+ T cells in the female genital tract is unknown, however, higher cell counts may suggest the potential for more HIV target cells in the genital tract.</description>
          <population>The analysis includes all available data collected during each study visit. Not all participants provided a sample at every study visit.</population>
          <units>cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42,000,000" spread="0.0"/>
                    <measurement group_id="O2" value="20,000,000" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15,000,000" spread="0.0"/>
                    <measurement group_id="O2" value="18,700,000" spread="7,500,000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20,000,000" spread="0.0"/>
                    <measurement group_id="O2" value="28,300,000" spread="8,500,000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30,000,000" spread="0.0"/>
                    <measurement group_id="O2" value="21,800,000" spread="13,200,000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steady-state Area Under the Plasma Concentration-time Curve of Study Drug</title>
        <description>Study drug concentrations will be measured from blood.</description>
        <time_frame>7 days</time_frame>
        <population>Data were not collected at each visit as some participants declined providing samples. Due to the small number of observations, study drug concentrations were not determined for the samples provided.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Women randomized to receive one tablet of Truvada (200mg emtricitabine/300mg tenofovir) daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc</title>
            <description>Women randomized to receive 300mg of Maraviroc daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Steady-state Area Under the Plasma Concentration-time Curve of Study Drug</title>
          <description>Study drug concentrations will be measured from blood.</description>
          <population>Data were not collected at each visit as some participants declined providing samples. Due to the small number of observations, study drug concentrations were not determined for the samples provided.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steady-state Area Under the Female Genital Tract Concentration-time Curve of Study Drug</title>
        <description>Study drug concentrations will be measured from female genital tract.</description>
        <time_frame>7 days</time_frame>
        <population>Data were not collected at each visit as some participants declined providing samples. Due to the small number of observations, study drug concentrations were not determined for the samples provided.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Women randomized to receive one tablet of Truvada (200mg emtricitabine/300mg tenofovir) daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc</title>
            <description>Women randomized to receive 300mg of Maraviroc daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Steady-state Area Under the Female Genital Tract Concentration-time Curve of Study Drug</title>
          <description>Study drug concentrations will be measured from female genital tract.</description>
          <population>Data were not collected at each visit as some participants declined providing samples. Due to the small number of observations, study drug concentrations were not determined for the samples provided.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded during the entire duration of participation for each individual subject, from signing the consent form through the 21 day follow up period.</time_frame>
      <desc>Genitourinary symptoms will be recorded at each visit. Signs and symptoms will be graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December 2004.</desc>
      <group_list>
        <group group_id="E1">
          <title>Truvada</title>
          <description>Women randomized to receive on tablet of Truvada daily for 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Maraviroc</title>
          <description>Women randomized to receive 300mg of Maraviroc 300 mg daily for 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In 2016, preliminary data analyses of a prior study and similar trials suggested minimal effects of a standard dose of maraviroc alone on cells of the female genital tract. Thus this intervention was discontinued early to minimize participant burden.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Anandi Sheth, MD</name_or_title>
      <organization>Emory University</organization>
      <phone>404-616-6240</phone>
      <email>ansheth@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

